Kyowa Kirin Co., Ltd.

Investor-Grade Deep Dive Research Report — March 2026 — Prepared by Ada Cockpit

Executive Summary

Kyowa Kirin Co., Ltd. (TSE: 4151) is a Japan-based global specialty pharmaceutical company focused on biotechnology-driven pharmaceuticals for unmet medical needs, particularly in rare diseases, nephrology, oncology, and immunology. Headquartered in Tokyo's Otemachi Financial City Grand Cube, the company was founded in 1949 and employs 5,669 people globally (as of December 31, 2024). It is a consolidated subsidiary of Kirin Holdings Company, Limited (55.2% ownership).[1][3]

¥495.6B FY2024 Revenue +12.1% YoY
¥95.4B Core Operating Profit -1.4% YoY
19.3% Core OP Margin Target: 30% by early 2030s
¥59.9B Net Income -26.3% YoY
72% Overseas Revenue Ratio Up from 65% in FY2023
5,669 Employees Consolidated, Dec 2024
¥1.38T Market Capitalization ~$9.2B USD
25.2x P/E Ratio (2025) Sector avg: 12.6x

The appointment of Abdul Mullick as President and CEO in March 2026, the first non-Japanese leader in the company's history, signals a deepening commitment to global operations. With a pipeline anchored by rocatinlimab (anti-OX40 for atopic dermatitis) and ziftomenib (menin inhibitor for AML), the company has significant optionality for growth beyond its current commercial portfolio.[8][9][10]

Vision 2030 Targets (Early 2030s): Core operating margin 30% | ROE low-10% | 20+ pipeline candidates | 10+ FDA-approved indications | Progressive dividend (DOE ≥4%)
FY2024 Revenue Mix by Region
Japan 37.9% NA 26.2% EMEA 21.2% APAC 10.4% Other 12.1%
Revenue Growth Trajectory (FY2020-FY2025E)
500 450 400 350 300 250 ¥ Billions 304.5 350.8 392.5 442.2 495.6 478.0E FY20 FY21 FY22 FY23 FY24 FY25E

1. Company History

Origins (1930s-1949)

Kyowa Kirin traces its roots to the 1930s Japanese fermentation industry. In 1936, three major distilled spirits manufacturers jointly established the Kyowa Chemical Research Institute in Tokyo. Following post-WWII corporate restructuring, Kyowa Hakko Kogyo Co., Ltd. was officially established on July 1, 1949.[2][14]

Key Milestones

YearMilestone
1949Kyowa Hakko Kogyo established; listed on Tokyo Stock Exchange
1951Partnership with Merck for streptomycin manufacturing
1956World-first fermentation process for L-glutamic acid; Mitomycin C mass production
2003BioWa, Inc. established in US for antibody business
2008Merger with Kirin Pharma; formed Kyowa Hakko Kirin
2012Poteligeo (mogamulizumab) approved in Japan
2018Crysvita (burosumab) FDA approved; Poteligeo FDA approved
2019Rebranded to Kyowa Kirin Co., Ltd.
2024Orchard Therapeutics acquisition completed ($387-478M)
2024Kura Oncology/ziftomenib collaboration ($330M upfront)
2026Abdul Mullick becomes first non-Japanese CEO

2. Ownership Structure

Kyowa Kirin is publicly listed on the Tokyo Stock Exchange (Prime Market) under ticker 4151. It is a consolidated subsidiary of Kirin Holdings Company, Limited (TSE: 2503), which holds a controlling 55.2% stake.[3][21]

Major Shareholders (December 31, 2024)

ShareholderShares HeldOwnership (%)
Kirin Holdings Company, Limited288,819,00055.19
The Master Trust Bank of Japan (Trust)53,378,80010.20
Custody Bank of Japan (Trust)24,942,200~4.77
Nomura Asset Management17,037,2003.25
BlackRock, Inc.10,865,9372.08
State Street Bank 5050253,279,6050.63

Board of Directors (March 2026)

NameRoleIndependent
Masashi MiyamotoRepresentative Director, ChairmanNo
Abdul MullickRepresentative Director, President & CEONo
Takeyoshi YamashitaDirector, EVP & CMONo
Takeshi MinakataDirectorNo
Takashi OyamadaOutside DirectorYes
Akira MoritaOutside DirectorYes
Rumiko NakataOutside DirectorYes
Yoshihisa SuzukiOutside DirectorYes
Jun AraiOutside DirectorYes

3. Leadership / C-Suite

Abdul Mullick, Ph.D. — President & CEO

First non-Japanese CEO in Kyowa Kirin's history. Ph.D. in Molecular Biology, University of Bristol; B.Sc., Kingston University. Over 25 years of pharmaceutical leadership across Hoechst Marion Roussel/Sanofi-Aventis (diabetes marketing), Novartis (diabetes brands), Genzyme/Sanofi (rare diseases), and Vifor Pharma. Joined Kyowa Kirin International in 2018 as Rare Disease Head; became President of KKI in 2019; relocated to Tokyo in 2023 as Chief International Business Officer. Appointed President & COO March 2025; elevated to CEO March 2026.[8][26][27]

Masashi Miyamoto, Ph.D. — Chairman

Ph.D., Graduate School of Pharmaceutical Sciences, University of Tokyo. Joined Kirin Brewery (now Kirin Holdings) in 1985. Rose through regulatory affairs and strategic planning at Kyowa Hakko Kirin. President since March 2018; CEO from April 2024. Transitioned to Chairman in March 2026.[28][29]

Other C-Suite Executives

NameTitleResponsibilitySince
Motohiko KawaguchiManaging Exec. Officer, CFOFinance, IRApr 2024
Colin SimsCFO (incoming)Procurement, FinanceMar 2026
Takeyoshi YamashitaEVP, CMOMedical Affairs, R&D, IP2025
Yoshifumi ToriiCSOGlobal Product StrategyMar 2026
Shoko ItagakiCPOHuman Resources, General Affairs2025
Steve SchaeferPresident, North AmericaKKNA business unitApr 2023
Hiroshi SonekawaManaging Exec. OfficerHead, Sales & Marketing2025

4. Drug Portfolio

Key Products Summary (FY2024)

ProductRevenue (FY2024 est.)GrowthPatent/ExclusivityPeak SalesP&L Owner
Crysvita (burosumab)~¥150-160B global+24-47% by regionUS Orphan Excl. expired Apr 2025; BPCIA to ~2030¥200B+ targetKyowa Kirin (global)
Poteligeo (mogamulizumab)~¥30-35B global+10-38% by regionUK orphan to Aug 2027; US BPCIA to ~2030¥50-60B est.Kyowa Kirin (global)
Fasenra royalties¥31.4B+15%AstraZeneca manages IPGrowing streamAstraZeneca (commercial)
G-Lasta (pegfilgrastim)¥20.5B (Japan)-35.7%Biosimilar competition activeDecliningKK Japan
Duvroq (daprodustat)¥15.5B (Japan)+91%Licensed from GSKGrowingKK Japan
Nesp/AG (darbepoetin)¥11.6B+AG (Japan)-19% (Nesp)Biosimilar competitionDecliningKK Japan
PHOZEVEL (tenapanor)Growing (new)Launched Feb 2024Licensed from ArdelyxGrowingKK Japan
Lenmeldy (gene therapy)ModestEarly stageOrphan drug; FDA Mar 2024NicheOrchard (KK sub)

Crysvita (Burosumab) — Flagship

Fully human monoclonal antibody targeting FGF23 for X-linked hypophosphatemia (XLH) and tumor-induced osteomalacia (TIO). Co-developed with Ultragenyx. Available in 52 countries, delivered to ~7,000 patients. US net product revenue $410M in FY2024 (+25% YoY). Kyowa Kirin became exclusive US commercial entity in April 2023. Standard of care for XLH with no approved competitor of comparable efficacy.[6][40][42]

Poteligeo (Mogamulizumab) — POTELLIGENT Platform Product

Anti-CCR4 antibody enhanced via proprietary POTELLIGENT technology (fucose removal for dramatically enhanced ADCC). Approved for relapsed/refractory cutaneous T-cell lymphoma (MF/SS). Growing double-digits across all regions. Orphan drug exclusivity provides competitive protection in a niche oncology market.[17][46][47]

Fasenra (Benralizumab) — Royalty Stream

Anti-IL-5Rα antibody discovered by Kyowa Kirin, developed using POTELLIGENT technology. Licensed to MedImmune/AstraZeneca for global commercialization (ex-Japan/Asia). FY2024 royalties: ¥31.4B (+15%); FY2025: ¥38.1B (+21%). The global benralizumab market was $1.69B in 2024, projected to reach $2.98B by 2030.[49][50][51]

5. Top 5 CEO Focus Drugs

#DrugIndicationFY2024 StatusStrategic Rationale
1CrysvitaXLH/TIO~¥150-160B; +24-47% growthFoundation revenue; global standard of care
2RocatinlimabAtopic dermatitisPh3 complete; filing H1 2026Peak sales ¥200B+; largest pipeline bet
3ZiftomenibAMLApproved R/R; Ph3 frontlineOncology platform via Kura deal ($330M+)
4PoteligeoCTCL~¥30-35B; +10-38% growthGrowing niche oncology; POTELLIGENT showcase
5FasenraSevere asthma¥31.4B royalties; +15%Passive income funding R&D investment

6. P&L Owners

Kyowa Kirin does not publicly disclose individual product-level P&L ownership by named franchise leads. The company organizes by geography and therapeutic area.

Business AreaNamed LeaderRole
North AmericaSteve SchaeferPresident, North America
NA FinanceAna Bastiani-PosnerEVP, CFO North America
NA Legal/ComplianceTara D'OrsiEVP, CCO & General Counsel
Japan Sales & MarketingHiroshi SonekawaManaging Exec. Officer, VP
Global Product StrategyYoshifumi ToriiChief Strategy Officer
R&D / Medical AffairsTakeyoshi YamashitaEVP & CMO
General Medicines BUNot publicly confirmedSenior VP, BU Leader
Neuroscience BUNot publicly confirmedSenior VP, BU Leader

7. R&D Pipeline

R&D spending increased to 23% of revenue in FY2025 (from 21% in FY2024). Strategic focus: immunology, oncology, rare diseases, gene therapy, and ophthalmology.[11]

ProgramMechanismIndicationPhasePartnerKey Milestone
RocatinlimabAnti-OX40Atopic dermatitisPhase 3 (done)Amgen (returned)Filing H1 2026
RocatinlimabAnti-OX40Prurigo nodularisPhase 3—Enrollment completing
ZiftomenibMenin inhibitorAML (frontline)Phase 3Kura OncologyKOMET-017 enrolled
ZiftomenibMenin inhibitorAML (FLT3/NPM1)Phase 2Kura OncologyKOMET-007 ongoing
KHK4951Tivozanib eye dropsWet AMD, DMEPhase 2—Data 2026-2027
OTL-200/LenmeldyHSC gene therapyMLDApproved—US commercial ramp
OTL-203HSC gene therapyMPS-IH (Hurler)Clinical—Data expected
OTL-201HSC gene therapyMPS-IIIA (Sanfilippo)Clinical—Data expected
BI programsSmall moleculesAutoimmune/fibro-inflam.PreclinicalBoehringer Ingelheim€1.05B total potential
KK8123UndisclosedBone/mineralEarly—Next-gen Crysvita

8. Top Geographies

RegionRevenue (¥B)% of TotalYoY ChangeKey Drivers
Japan187.837.9%-8%NHI cuts; G-Lasta/Nesp decline; Duvroq/PHOZEVEL growth
North America130.026.2%+27%Crysvita +24%, Poteligeo +38%
EMEA105.221.2%+16%Crysvita +47%, Poteligeo +19%, IP transfer
APAC51.510.4%+47%Crysvita growth, inventory transfers
Other (royalties)59.912.1%+24%Fasenra royalties ¥31.4B, BI upfronts
Key trend: Overseas revenue ratio expanded from 65% in FY2023 to 72% in FY2024. North America is the fastest-growing major region. Japan remains the largest single market but is shrinking structurally.

9. Competitive Landscape

XLH (Rare Disease)

CompanyProduct/PipelinePosition
Kyowa Kirin / UltragenyxCrysvita (burosumab)Market leader, standard of care
Ascendis PharmaPipeline candidateClinical development
Conventional therapyOral phosphate + vitamin DInferior efficacy

Atopic Dermatitis (Immunology)

CompanyProductEfficacy (EASI-75)
Sanofi / RegeneronDupixent (dupilumab)~65-70%
AbbVieRinvoq (upadacitinib)~60-70%
Eli LillyEbglyss (lebrikizumab)~50-60%
Kyowa KirinRocatinlimab32-42%

AML (Oncology)

CompanyProductClass
Kura / Kyowa KirinZiftomenib (KOMZIFTI)Menin inhibitor
SyndaxRevuforj (revumenib)Menin inhibitor
AbbVieVenclexta (venetoclax)BCL-2 inhibitor
Daiichi SankyoVanflyta (quizartinib)FLT3 inhibitor

10. Risks and Challenges

1. Rocatinlimab Execution Risk: Amgen's exit and "underwhelming" Phase 3 efficacy (32-42% EASI-75 vs. Dupixent's ~65-70%) raise questions about commercial viability. Safety signals and gastrointestinal ulceration concerns add uncertainty. The company's ¥200B+ peak sales target appears ambitious.[9][54][56]
2. Japan Revenue Erosion: Biennial NHI price cuts and biosimilar competition are structurally eroding G-Lasta (-36%), Nesp (-19%), and other legacy products. Japan revenue declined 8% in FY2024.[5][35]
3. Crysvita Patent/Exclusivity Cliff: US orphan drug exclusivity expired April 2025. BPCIA 12-year protection extends to ~2030, but long-term revenue sustainability requires lifecycle management.[44][45]
4. Concentration Risk: Crysvita represents an estimated 30-35% of total revenue. Over-reliance on a single rare disease product creates vulnerability.[6]
5. Kirin Holdings Controlling Shareholder: The 55.2% ownership may create governance conflicts between parent priorities and minority shareholder interests.[3][22]
6. Currency Volatility: With 72% overseas revenue and JPY reporting, the ¥24.4B FX tailwind in FY2024 could reverse if JPY strengthens.[6]
7. R&D vs. Profitability Tension: R&D at 23% of revenue exceeds the 18-20% target range. Core OP margin declined to 19.3% (vs. 30% target). Pipeline conversion is essential.[11]

11. Outlook and Valuation Context

Near-Term (FY2025-2026)

FY2025 is a "transition year": revenue guided at ¥478B (-3.5%), core OP at ¥80B (-16.1%). FY2026 catalysts include rocatinlimab regulatory submissions, ziftomenib frontline data, and continued Crysvita/Poteligeo growth.[6]

Medium-Term Growth Drivers (2027-2030)

Rocatinlimab launch (if approved, first revenues 2027-2028), ziftomenib frontline AML expansion, Crysvita lifecycle management, gene therapy maturation, and Boehringer Ingelheim milestones (€1.05B potential).

Valuation Metrics

MetricValueContext
Market Cap¥1.38T (~$9.2B)—
P/E (2025)25.2xSector avg: 12.6x
Forward P/E (2026)20.9x—
EV/Sales (2025)2.4x—
Price-to-Book1.6x—
Dividend Yield~2.3%¥62/share FY2025
Analyst ConsensusOUTPERFORMTarget ¥2,595 (range 2,000-3,200)

Dividend Policy (FY2026 onward)

FYDividend/ShareYoY ChangePolicy
FY2024¥58+¥640% core EPS payout
FY2025¥62+¥440% core EPS payout
FY2026 (plan)¥70+¥8DOE ≥4%; progressive; 10th consecutive increase

12. Patent/Exclusivity Summary Table

ProductMarketProtection TypeStatus/Expiry
CrysvitaUSOrphan Drug Exclusivity (XLH)Expired April 17, 2025
CrysvitaUSBPCIA 12-year biologics data exclusivity~2030
CrysvitaCanadaPatent protectionFebruary 14, 2028
CrysvitaEUData/market exclusivity10 years from approval
PoteligeoAustraliaPatentExpired October 1, 2024
PoteligeoUK/NIOrphan market exclusivityAugust 15, 2027
PoteligeoUSBPCIA 12-year biologics exclusivity~2030
PoteligeoEU10-year data/market exclusivityFrom Nov 2018 approval
G-LastaJapanBiosimilar competitionActive erosion
NespJapanBiosimilar competitionSignificant share loss
LenmeldyUSOrphan Drug DesignationActive
LibmeldyEU/UKOrphan medicinal productActive

References

  1. Kyowa Kirin Corporate Overview
  2. The Shashi - Kyowa Hakko Kogyo History
  3. Kyowa Kirin Corporate Governance Report 2025
  4. Investing.com - Kyowa Kirin Stock Data
  5. Kyowa Kirin FY2024 Financial Summary
  6. Kyowa Kirin FY2024 Results Presentation
  7. Kyowa Kirin FY2024 Earnings Transcript
  8. Abdul Mullick CEO Appointment
  9. Amgen Returns Rocatinlimab Rights
  10. Kura Oncology / Kyowa Kirin Ziftomenib Collaboration
  11. Kyowa Kirin FY2025 Results Presentation
  12. Kyowa Kirin Vision 2030 and Beyond
  13. Kyowa Kirin Dividend Information
  14. Kyowa Kirin History
  15. Wikipedia - Kyowa Kirin
  16. KKNA History
  17. POTELLIGENT Technology
  18. POTELLIGENT Technology - PMC Article
  19. Orchard Therapeutics Acquisition
  20. Kyowa Kirin Acquires Orchard
  21. Kyowa Kirin Ownership History
  22. Integration Agreement
  23. SimplyWall.St - Ownership
  24. MarketScreener Governance
  25. Kyowa Kirin Directors & Officers
  26. Abdul Mullick Bio
  27. Abdul Mullick - Mereo Board
  28. Masashi Miyamoto Bio
  29. Miyamoto Chairman Announcement
  30. Motohiko Kawaguchi - Bloomberg
  31. Management Changes Feb 2026
  32. Organizational Changes Aug 2025
  33. Steve Schaefer Appointment
  34. KKNA Leadership
  35. FY2024 Appendix
  36. Q3 2024 Presentation
  37. Q2 2024 Presentation
  38. Q1 2024 Presentation
  39. FDA Lenmeldy Review
  40. Crysvita XLH Data
  41. XLH Study Data
  42. Ultragenyx SEC Filing - Crysvita US Revenue
  43. XLH Market Report
  44. FDA Orphan Drug Designation - Crysvita
  45. DrugPatentWatch - Crysvita
  46. Poteligeo RWE Data
  47. DrugPatentWatch - Poteligeo
  48. UK Tender - Poteligeo Exclusivity
  49. Fasenra Royalties FY2024
  50. Fasenra Royalties FY2025
  51. Benralizumab Market Report
  52. MLD Foundation - Gene Therapy
  53. Rocatinlimab Peak Sales Projection
  54. Rocatinlimab IGNITE Phase 3
  55. Rocatinlimab HORIZON Phase 3
  56. Amgen Returns Rocatinlimab
  57. KOMET-017 First Patient
  58. KKNA Leadership Page
  59. KHK4951 DME Trial
  60. Boehringer Ingelheim Deal - Jan 2024
  61. Boehringer Ingelheim Deal - Oct 2025
  62. Rocatinlimab Safety Signals
  63. MarketScreener FY2024 Results
  64. MarketScreener - Kyowa Kirin Analysis
  65. Kirin Holdings Integrated Report 2024
  66. Supplier Briefing 2024
  67. KKI Heritage Story
  68. Kirin Holdings Group Companies
  69. Fintel - Institutional Ownership
  70. Citeline - Mullick Profile
  71. Vision 2030 Strategy Page
  72. Financial Strategy Page
  73. MTBP 2021 Announcement
  74. StockAnalysis.com - TSE:4151
  75. TradingView - TSE:4151
  76. Grünenthal JVC Announcement
  77. Grünenthal Full Ownership
  78. BioWa Out-Licensing
  79. BioWa Homepage
  80. Strategic Partnering
  81. R&D Structure
  82. Pipeline Page
  83. Fujifilm Kyowa Kirin Biologics
  84. Crysvita EU Royalty Sale
  85. Crysvita NA Royalty Sale
  86. PEG-rhG-CSF Market
  87. BioSpace - Amgen Exits Alliance
  88. Fierce Biotech - Amgen Exits Pact
  89. Integrated Report 2023

This report was prepared using publicly available information as of March 2026. All financial figures are in Japanese Yen (¥) unless otherwise noted. Exchange rates used by the company for FY2024: USD/JPY 151, EUR/JPY 164, GBP/JPY 191. This report does not constitute investment advice.

Kyowa Kirin Deep Dive — Ada Cockpit — March 2026